151 related articles for article (PubMed ID: 15986594)
1. Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
Fakhrai N; Haitel A; Balassy C; Zielinski CC; Schmidinger M
Wien Klin Wochenschr; 2005 Jan; 117(1-2):63-5. PubMed ID: 15986594
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
Staehler M; Haseke N; Schöppler G; Stadler T; Karl A; Siebels M; Ihrler S; Stief CG
Eur J Med Res; 2008 Nov; 13(11):531-5. PubMed ID: 19073390
[TBL] [Abstract][Full Text] [Related]
3. [Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
Kullmann T; Pintér T; Szepesvári Z; Kránitz N; Culine S
Orv Hetil; 2016 Mar; 157(11):436-9. PubMed ID: 26947093
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
Staehler M; Schöppler G; Haseke N; Stadler T; Karl A; Siebels M; Ihrler S; Stief CG
Clin Genitourin Cancer; 2009 Jan; 7(1):58-61. PubMed ID: 19213670
[TBL] [Abstract][Full Text] [Related]
5. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
Milowsky MI; Rosmarin A; Tickoo SK; Papanicolaou N; Nanus DM
Cancer; 2002 Jan; 94(1):111-6. PubMed ID: 11815966
[TBL] [Abstract][Full Text] [Related]
6. ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
Bannowsky A; Wefer B; Naumann M; Hamann M; Hautmann S; Jünemann KP
Urologe A; 2005 Aug; 44(8):915-7. PubMed ID: 15942775
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract][Full Text] [Related]
8. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
[TBL] [Abstract][Full Text] [Related]
10. [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
Inoue T; Ohyama C; Hatakeyama S; Horikawa Y; Togashi H; Tsuchiya N; Matsuura S; Satoh S; Sato K; Habuchi T
Hinyokika Kiyo; 2005 Mar; 51(3):165-9. PubMed ID: 15852669
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
13. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
14. A renal cancer with intermediate characteristics between collecting (Bellini) duct carcinoma and urothelial carcinoma: case report and review of the literature.
Maestroni U; Ferretti S; Dinale F; Froio E; Pilato FP; Ciuffreda M; Mellissari M; Cortellini P
Tumori; 2006; 92(6):545-8. PubMed ID: 17260499
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Ryan CW; Vogelzang NJ; Stadler WM
Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
[TBL] [Abstract][Full Text] [Related]
16. Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab.
Barrascout E; Beuselinck B; Ayllon J; Bättig B; Moch H; Teghom C; Oudard S
Am J Case Rep; 2012; 13():1-2. PubMed ID: 23569471
[TBL] [Abstract][Full Text] [Related]
17. Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Hoshi S; Satoh M; Ohyama C; Hiramatu M; Watanabe R; Hagisawa S; Endo M; Arai Y
Int J Clin Oncol; 2003 Apr; 8(2):113-7. PubMed ID: 12720105
[TBL] [Abstract][Full Text] [Related]
18. [Carcinoma of the Bellini collecting duct in paediatric patients: a case report and review of the literature].
Gurrera A; Amico P; Di Cataldo A; Vasquez E; Magro G
Pathologica; 2007 Oct; 99(5):301-5. PubMed ID: 18354951
[TBL] [Abstract][Full Text] [Related]
19. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases.
Peyromaure M; Thiounn N; Scotté F; Vieillefond A; Debré B; Oudard S
J Urol; 2003 Oct; 170(4 Pt 1):1138-40. PubMed ID: 14501710
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Collecting (Bellini) Duct Carcinoma Presented in a Young Patient: A Case Report and Review of the Literature.
Klang E; Lawson P; Yonat H; Michal Amitai M
Isr Med Assoc J; 2017 Dec; 19(12):777-778. PubMed ID: 29235742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
